Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

Typhoid fever is a significant public health concern with most of the sufferers between 15 and 25 y of age in Nepal. We undertook this study to demonstrate Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT) conjugate vaccine which is non-inferior to Typbar typhoid conjugate vaccine, a Vi po...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dipesh Tamrakar, Pranodan Poudel, Pragya Thapa, Srijana Singh, Amit Khadgi, Sameera Thapa, Rajendra Tamrakar, Anmol Shrestha, Surendra Madhup, Ganesh Kumar Rai, Birendra Prasad Gupta, Tarun Saluja, Sushant Sahastrabuddhe, Rajeev Shrestha
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Typhoid conjugate vaccine observer-blind randomized phase III clinical trial
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2023.2301631
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

Similar Items